In a double-blind, placebo-controlled, crossover trial the effect of 2-mg nicotine chewing gum was studied in 43 smokers when they were smoking as inclined and when they were trying to stop smoking. Although 70O0 of the smokers stopped smoking during treatment, only 230" were still abstinent after one year. The effect of the nicotine, though significant, was small compared with the overall reduction in smoking. When the subjects were smoking as inclined cigarette consumption was reduced by an average of 37°O on the nicotine gum compared with 31o' on placebo gum, while average carboxyhaemoglobin (COHb) levels were reduced by 260/ and 150°on the active and placebo gums respectively. When subjects tried to stop smoking there was a further considerable reduction in cigarette consumption, but no longer any difference between the two gums. Nevertheless, average COHb was still lower on the active gum. Plasma nicotine levels on the nicotine gum averaged only 10 7 ng/ml compared with 27-4 ng/ml after smoking. Better results could be expected with 4-mg nicotine gums.
Introduction
Since the urge to smoke is probably related to a need for nicotine,' a chewing gum containing nicotine has been developed in Sweden,2 and preliminary results suggest that it may somewhat inhibit smoking3 and facilitate cigarette withdrawal. 4 Besides pharmacological substitution it also provides an alternative oral activity. We tested this gum therapeutically in dependent smokers and also examined its effect on smoking behaviour, including the intake of nicotine and carbon monoxide from smoking.
Subjects and methods
The nicotine chewing gum was supplied by AB Leo, Helsingborg, Sweden,2 and was of two strengths: 4 mg and 2 mg nicotine in each piece of gum. In pilot work before the trial we found the 4-mg gum too strong for many smokers. To avoid excessive dropping out and failure to adhere to the required dose we decided to use only the 2-mg gum. Placebo gum containing no nicotine was also provided. This was heavily spiced to match the sharp taste and local irritancy of nicotine. The nicotine was bound to an ion exchanger that allowed it to be released slowly over 20 to 30 minutes as the gum was chewed, the rate of release being related to the vigour and rate of chewing. Because buccal absorption of nicotine is pH dependent, the chewing-gum contained a buffer to keep the pH in the mouth at about 8-5. Forty-three cigarette smokers from the Maudsley Hospital smokers clinic agreed to take part in a trial of nicotine chewing gum. Subjects were excluded if there was any suspicion of heart disease. There were 18 men and 25 women with ages ranging from 21 to 57 (average 37) years. They were eager to try this form of treatment and no one to whom it was offered refused or showed reluctance. Before admission to the trial the smokers completed an assessment interview, personality tests, questionnaires on smoking, and a detailed record of their usual cigarette consumption over a full week.
For the trial a strict attendance schedule covering three weeks was adopted. This required attendance on Monday, Wednesday, and Friday of the first week. During this week subjects were given the chewing gum but were instructed to smoke as they felt inclined and not to make any deliberate attempt to cut down their cigarette consumption. They took either 2-mg nicotine gum or placebo gum for two days (Monday to Wednesday), after which the gums were switched for the next two days (Wednesday to Friday). Half the subjects had the active gum first and the other half the placebo first in a randomised crossover design. Over the weekend of the first week the subjects "rested." They were allowed to smoke freely; they took no gum and kept no record of their smoking.
From Monday morning of the second week they started once again to take the gum regularly and tried their best to stop smoking. They were seen at the clinic the following Monday. At this fourth visit they were given support and encouragement, and the gum was changed for the third and final week. Once again the crossover of the active and placebo gums was balanced, the order being the same as for the first week.
The design allowed comparison of the nicotine and placebo gum over four days of unrestricted smoking and then over two weeks during which the smokers were trying to give up smoking. Subjects were seen individually and were unaware that one of the gum preparations was a placebo, believing that the comparison was between different kinds of nicotine gum. The therapist was also unaware of the identity of the gum so that the comparison was double-blind. Cigarette consumption was recorded in a special booklet. All subjects were instructed to chew 10 gums a day. They took the first at a convenient time after waking and then took one each hour, on the hour, until they had chewed seven pieces. The remaining three pieces were taken at twohourly intervals. Each piece had to be chewed for at least 20 minutes. The dose schedule and instructions were clearly written in the smoking record booklet.
Venous blood samples were taken at all five attendances. Subjects attended in the afternoon, and the samples from each subject were taken at roughly the same time on each visit. On the first three occasions, when the subjects were smoking as inclined, they were asked to smoke a cigarette and the blood sample was then taken about two minutes after the cigarette was completed. This was done to standardise the period after the last cigarette. They were not, however, asked to do this on the fourth and fifth occasions, when they were trying to stop smoking. The samples were analysed for carboxyhaemoglobin (COHb) using an IL 182 CO-Oximeter5 and for nicotine using gas chromatography. 6 Visual analogue scales were used to compare the different gums on subjective ratings of "strength," "satisfaction," "taste evaluation," "nausea induction," and the "effect on desire for cigarettes." We have found the test-retest reliability of such ratings to be satisfactory (r =0.91).7
After the five scheduled attendances a flexible approach was adopted. Subjects were offered as much support and follow-up as required or desired. They continued on the gum of their choice, but took it when they felt it was necessary rather than on schedule. Postal follow-up was done monthly after subjects stopped attending. The final followup was done at least one year after treatment. All subjects claiming abstinence at this stage were seen again and had their blood checked for COHb and nicotine. Subjects who dropped out or failed to submit follow-up data were assumed to have relapsed to their former level of consumption.
Results
The effect of the chewing gum on cigarette consumption, COHb levels, and plasma nicotine levels is shown in table I.
CIGARETTE CONSUMPTION
During recording average cigarette consumption was 9% less than originally claimed (36-7 v 33-3 cigarettes per day; t=2-8; DF=42; P<0 01). A further reduction of 31 % (base=33-3; t=4-7; P<0-001) was achieved on the placebo gum compared with 37% on the nicotine gum, despite no deliberate effort to cut down on the part of the smoker.
The small difference in favour of the active gum (20-9 v 23-0 cigarettes a day) when smoking as inclined was statistically significant (t=2-2; P <005). The major decline in consumption occurred when the subjects also tried to stop smoking. Average consumption then dropped to 4-1 and 3 9 cigarettes a day on the active and placebo gums respectively, which was not a significant difference. The order in which the gums were taken did not have a significant effect.
COHB LEVELS
When smoking as inclined the COHb level decreased by an average of 15% on placebo gum and 26% on nicotine gum, and the average COHb level of 6-3% on the nicotine gum was significantly lower than the average of 722% on the placebo gum (t=2-97; P < 001). The levels were much lower when the subjects were trying not to smoke, and, though very small, the difference in favour of the active gum was statistically significant (2-3 % v 2-9%; t=2 5; P<0-02). The order in which the gums were taken had no significant effect on COHb levels.
PLASMA NICOTINE LEVELS
When the subjects had been taking gum and smoking as they felt inclined the average plasma nicotine levels two minutes after a cigarette were not significantly different on the active and placebo gums (27-4 and 24-7 ng/ml respectively; t= 1-8; DF = 32). Furthermore, on the nicotine gum the plasma nicotine level did not differ significantly from the initial level before taking any gum, but on the placebo gum it was a little less (24-7 v 30-1 ng/ml; t=2-4, DF=34; P < 0-05). When the subjects were trying not to smoke (and had not been required to smoke just before blood sampling) their plasma nicotine levels were very much lower (P < 0-001); but the level on the nicotine gum was only a little more than that on the placebo gum (10-7 v 7-3 ng/ml respectively; t= 2-4; P <0-05). Plasma nicotine levels were unaffected by the order in which the nicotine and placebo gums were taken.
SUCCESS RATE AT GIVING UP SMOKING
The number of subjects who successfully stopped smoking during treatment and over one year of follow-up are shown in table.2 Five subjects failed to complete the three-week treatment schedule. Three of them claimed excessive pressures at work or from domestic problems, but they also had prominent side effects from the gum (see below). The other two drop-outs did not complain of adverse effects and gave no reasons, but they had already been lax about recording their smoking. One-year follow-up data were obtained on all but eight subjects. Seven of these were already known to have relapsed earlier, and the remaining one, who had been abstinent at six months, was classified as having relapsed by seven months. The order in which the gums were given did not affect success rate. Abstinence from smoking was confirmed by checking COHb levels. In one person claiming abstinence it was 6-0 %; he was classified as a failure.
Initial cigarette consumption, plasma nicotine, COHb, and the sex of the subjects had no relation to their success in giving up smoking, but none of the 12 subjects under 30 years were among the 10 still abstinent at one year's follow-up (P < 0 05; Fisher's exact test). 
SUBJECTIVE EFFECTS OF NICOTINE GUM
Helpfulness as a stubstitute for smoking-Subjective opinions of the helpfulness of the gum in reducing the urge to smoke and easing cigarette withdrawal symptoms are shown in table III. Only 10 people found neither gum helpful. The placebo was preferred by only one person and the active gum was clearly more helpful, especially to those who were able to stop smoking. By six weeks most subjects had either abandoned their attempt to give up smoking or no longer required any gum. There were three exceptions who became dependent on the nicotine gum. Two of them relapsed to smoking when they ran out of gum after five and six months; the other was weaned off it at 10 months without resorting to smoking.
Rating scale scores-Average ratings of the nicotine and placebo gums after they had been taken for a week differed significantly but not greatly. The average scores and significance levels on two-tailed t tests were as follows (scores for nicotine gum are given first): nicotine gum was more "satisfying" (58 v 44; P < 0 01), more "nauseating" (33 v 18; P=0 001), "stronger" (55 v 34; P<0 005), and subjects were more "put off cigarettes" by it (63 v 54; P < 0 05), but it also had a less "good taste" (50 v 60; P < 0 02).
Side effects-Mild and transient unwanted effects were common, especially with the nicotine gum. They were experienced by 22 subjects, seven of whom also had complaints about the placebo gum. Side effects were more severe in 10 subjects, and eight of them were forced to discontinue the gum for a while. The side effects experienced, with number of subjects in parentheses, were as follows: sore mouth or throat (11), including ulceration of the tongue (2); nausea (12), including vomiting (3); flatulence, indigestion, or an epigastric burning sensation (7); hiccups (2); faintness or dizziness (3); laxative effect (1). Neither gum helpful (n = 10) 5 5 Only placebo gum helpful 0 0
Only nicotine gum helpful (n= 16) 
Discussion
The overall effect of attending the clinic and trying to give up smoking with the help of nicotine chewing gum was substantial.
Average cigarette consumption and COHb levels were greatly reduced (table I); 700, of the subjects stopped smoking during the treatment, and 23°00 were still abstinent after one year. In this respect the results are similar to those on many other treatment methods used at our clinic8 and reported. 9 10 Many factors affect the outcome of a treatment and, though significant, the specific contribution of nicotine was small, amounting to 700 of the total reduction in cigarette consumption and 1500 of the total reduction in COHb level. Of greater influence was the combined effect of spending five hours a day chewing gum and the placebo effect of the subjects' belief that the gum being chewed contained nicotine. Since there was no control condition in which subjects chewed a gum that they knew did not contain nicotine, we could not assess how much the effect of the placebo gum was due to the time spent chewing and how much was true "placebo effect." The greatest effect occurred when the subjects actually tried to stop smoking, but the study was not designed to assess how much of this was owing to such factors as the subjects' own efforts, interaction with the effect of the chewing-gum, and the support and discipline of attending the clinic. The presence of nicotine in the gum affected smoking behaviour in two ways. It reduced both the number of cigarettes smoked and the degree of inhalation of these cigarettes. This is shown by the proportionally greater effect of nicotine in reducing COHb levels (I 5°o) than in reducing cigarette consumption (700). Part of the COHb reduction was due to fewer cigarettes being smoked, but a roughly equal part must have been due to a reduction in the degree of inhalation of the cigarettes smoked. This shows again that smokers regulate their nicotine intake in more ways than just changing the number of cigarettes smoked.
Our findings show a clear, though modest, inhibitory effect on smoking behaviour when nicotine is introduced from another source and as such provide direct evidence that nicotine is an important determinant of smoking. This inhibitory effect was clearly apparent only when subjects were smoking as they felt inclined and was largely swamped by other factors (subjects' efforts, clinic support, etc) once the subjects tried not to smoke. Despite the relative weakness of the nicotine effect, undoubtedly the subjects found the nicotine gum more helpful and satisfying than the placebo gum. Furthermore, three people became dependent on the nicotine gum; and this did not happen with the placebo gum.
One reason for the relative weakness of the nicotine effect may have been inadequate dosage; 2-mg nicotine chewing gum probably corresponds to no more than about half a cigarette. We have shown" that 4-mg nicotine gum is required for plasma nicotine levels to approximate to those obtained by smoking. We opted to use the 2-mg gum after pilot work showed that the 4-mg gum was too strong for many smokers. Even with the 2-mg gum side effects were a problem in about one in four subjects. The manufacturers have now, however, produced an improved brand of 4-mg gum, which is apparently more palatable.' 2 The plasma nicotine values when subjects were taking gum and trying not to smoke were low simply because the subjects were smoking less and had not been required to smoke just before blood sampling. They do show, however, that the nicotine gum did not produce levels even half as high as the peak levels just after smoking. The nicotine levels when taking gum and smoking as inclined are of more interest. The fact that on the nicotine gum they were not significantly higher than the initial level when smoking normally without gum supports the view that the individual smoking pattern is modified to regulate nicotine intake. When extra nicotine is available from the gum, cigarette consumption and the degree of inhalation are lowered just sufficiently to produce a constant plasma level. The fact that on the placebo gum the plasma nicotine was very slightly lower than when smoking without gum is against the nicotine self-regulation hypothesis. Possibly a self-regulation downwards is more sensitive and complete than compensation upwards.
